Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HA filler

Phase 3Small molecule

UUniversity of Pennsylvania

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

RegressionRecruiting

RegressionPhase 3

Recruiting

Timeline

Expected Milestones

Q4 2026

ApprovedRecruiting

Regression

NCT07777926

Clinical

Trials by Indication[1]

Prospective1 trial

A Prospective Evaluation of the Filler for Jaw Contouring

Completed·UUniversity of Pennsylvania·Phase 4·NCT06694857·14 enrolled

Regression1 trial

3-Dimensional Volumetric Analysis of a Hyaluronic Filler Injection for Chin Profile Enhancement

Recruiting·UUniversity of Pennsylvania·Approved·NCT07777926·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for HA filler. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HA filler compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HA filler. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Pennsylvania company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Pennsylvania

Related News